Antistoffer med krydsallergi over for humant insulin og insulin glargin sås i kliniske forsøg med samme frekvens i både NPH - insulin og insulin glargin behandlede grupper.
In clinical studies, antibodies that cross- react with human insulin and insulin glargine were observed with the same frequency in both NPH- insulin and insulin glargine treatment groups.